BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10096866)

  • 1. Chiral dihydroxylation of acronycine: absolute configuration of natural cis-1,2-dihydroxy-1,2-dihydroacronycine and cytotoxicity of (1R,2R)- and (1S,2S)-1,2-diacetoxy-1,2-dihydroacronycine.
    Costes N; Michel S; Tillequin F; Koch M; Pierré A; Atassi G
    J Nat Prod; 1999 Mar; 62(3):490-2. PubMed ID: 10096866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological activity of esters in the trans-1,2-dihydroxy-1,2-dihydroacronycine series.
    Magiatis P; Mitaku S; Skaltsounis AL; Tillequin F; Koch M; Pierré A; Atassi G
    J Nat Prod; 1998 Feb; 61(2):198-201. PubMed ID: 9514007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.
    Elomri A; Mitaku S; Michel S; Skaltsounis AL; Tillequin F; Koch M; Pierré A; Guilbaud N; Léonce S; Kraus-Berthier L; Rolland Y; Atassi G
    J Med Chem; 1996 Nov; 39(24):4762-6. PubMed ID: 8941390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New antitumor agents in the acronycine series].
    Tillequin F
    Ann Pharm Fr; 2002 Jul; 60(4):246-52. PubMed ID: 12378151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships in the acronycine and benzo[b]acronycine series: role of the pyran ring.
    Do Q; Thi Mai HD; Gaslonde T; Pfeiffer B; Léonce S; Pierré A; Michel S; Tillequin F; Dufat H
    Eur J Med Chem; 2008 Dec; 43(12):2677-87. PubMed ID: 18342404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and cytotoxic and antitumor activity of 1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine diacid hemiesters and carbamates.
    Doan Thi Mai H; Gaslonde T; Michel S; Koch M; Tillequin F; Pfeiffer B; Renard P; Kraus-Berthier L; Léonce S; Pierré A
    Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):293-7. PubMed ID: 14993749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and cytotoxic activity of acronycine derivatives modified at the pyran ring.
    Elomri A; Skaltsounis AL; Michel S; Tillequin F; Koch M; Rolland Y; Pierré A; Atassi G
    Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2165-8. PubMed ID: 8945782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and configuration of racemic and optically active analgesic dialkylaminoalkylnaphthalenes.
    Ghislandi V; Azzolina O; Collina S; Paroli E; Antonilli L; Giuseppetti G; Tadini C
    Chirality; 1994; 6(5):389-99. PubMed ID: 8068498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and cytotoxic activity of benzo[a]acronycine and benzo[b]acronycine substituted on the A ring.
    Gaslonde T; Covello F; Velazquez-Alonso L; Léonce S; Pierré A; Pfeiffer B; Michel S; Tillequin F
    Eur J Med Chem; 2011 May; 46(5):1861-73. PubMed ID: 21411193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzo[b]acronycine derivatives: a novel class of antitumor agents.
    Michel S; Gaslonde T; Tillequin F
    Eur J Med Chem; 2004 Aug; 39(8):649-55. PubMed ID: 15276298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Oxo-2-hydroxy-1,2-dihydroacronycine: a useful synthon in the acronycine series for the introduction of amino substituents at 6-position and for the conversion into isopropylfuroacridones.
    Magiatis P; Mitaku S; Skaltsounis AL; Tillequin F
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1304-7. PubMed ID: 11605659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Structure activity relationships and mechanism of action of antitumor benzo[b]acronycine antitumor agents].
    Seguin E; Tillequin F
    Ann Pharm Fr; 2005 Jan; 63(1):44-52. PubMed ID: 15803100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships in the acronycine series.
    Michel S; Seguin E; Tillequin F
    Curr Med Chem; 2002 Sep; 9(18):1689-700. PubMed ID: 12171551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From acronycine to benzo-[b]-acronycine derivatives: potent antitumor agents].
    Koch M
    Bull Acad Natl Med; 2007 Jan; 191(1):83-91; discussion 91-3. PubMed ID: 17645109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4.
    Pettit GR; Toki BE; Herald DL; Boyd MR; Hamel E; Pettit RK; Chapuis JC
    J Med Chem; 1999 Apr; 42(8):1459-65. PubMed ID: 10212132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute configuration of chloro-bisabolene sesquiterpene.
    Zhu Y; Yu KB; Jia ZJ
    Pharmazie; 2004 Jul; 59(7):513-5. PubMed ID: 15296086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship studies of new acronine analogues as suggested by molecular descriptors.
    Neto MR; DaCosta JB; Sant'Anna CM; Carneiro JW
    Arzneimittelforschung; 2005; 55(5):282-8. PubMed ID: 15960428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselective aliphatic hydroxylations of racemic 1-hydroxy-3-methylcholanthrene by rat liver microsomes.
    Shou MG; Yang SK
    Chirality; 1990; 2(3):141-9. PubMed ID: 2252843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.
    Khokhar AR; al-Baker S; Shamsuddin S; Siddik ZH
    J Med Chem; 1997 Jan; 40(1):112-6. PubMed ID: 9016335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acronycine derivatives: a promising series of anticancer agents.
    Nguyen QC; Nguyen TT; Yougnia R; Gaslonde T; Dufat H; Michel S; Tillequin F
    Anticancer Agents Med Chem; 2009 Sep; 9(7):804-15. PubMed ID: 19594412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.